Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 1/20 | 0.47 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.47 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.47 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.47 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.47 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.47 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.47 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435436 | 0.85 | MAPT (0.56) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL5675400 | 0.84 | PBRM1 (0.42) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL5674359 | 0.82 | CACNB4 (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL7463659 | 0.80 | BRD4 (0.51) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL28741441 | 0.80 | CACNB4 (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL5434201 | 0.79 | HTR7 (0.42) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL5677692 | 0.79 | CDYL2 (0.46) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL23721282 | 0.79 | LMNA (0.42) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL5858697 | 0.77 | CACNB4 (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL7471103 | 0.77 | MAPT (0.41) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| CN-1224623-C | 1-phenylsulfonyl-1, 3-dihydro-2H-indol-2-one derivatives, their preparation and their therapeutic use | SANOFI ANWANTE (FR) | 2005-10-26 | — | — | CN | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| EP-1419150-B1 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| EP-1296976-B1 | NOVEL 1,3-DIHYDRO-2H-INDOL-ONE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI AVENTIS (FR) | 2005-01-26 | — | — | EP | disclosed |
| CN-1533387-A | 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use | ����ɳŵ��-����������˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1419150-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2004-05-19 | — | — | EP | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| WO-2003008407-A2 | PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | AVPR1B, AVPR1A, AVPR2 | CACNB4 688/4885CACNA1A 171/4885CACNA1G 275/4885 |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | AVPR1B, AVPR2, AVPR1A | CACNB4 1113/4885CACNA1A 652/4885CACNA1G 636/4885 |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | AVPR2, AVPR1A, AVPR1B | CACNB4 262/4885CACNA1A 121/4885CACNA1G 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.